Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

Jan H. Beumer, Edward Chu, Carmen Allegra, Yusuke Tanigawara, Gerard Milano, Robert Diasio, Tae Won Kim, Ron H. Mathijssen, Li Zhang, Dirk Arnold, Katsuki Muneoka, Narikazu Boku, Markus Joerger

Research output: Contribution to journalReview articlepeer-review

16 Citations (Scopus)

Abstract

5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.

Original languageEnglish
Pages (from-to)598-613
Number of pages16
JournalClinical Pharmacology and Therapeutics
Volume105
Issue number3
DOIs
Publication statusPublished - 2019 Mar

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy'. Together they form a unique fingerprint.

Cite this